Skip to main content
Hemostemix Inc. logo

Hemostemix Inc. — Investor Relations & Filings

Ticker · HEM LEI · 984500C65BB0B8159L77 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 212 across all filing types
Latest filing 2025-09-15 Regulatory Filings
Country CA Canada
Listing TSXV HEM

About Hemostemix Inc.

https://hemostemix.com/

Hemostemix Inc. is a clinical-stage biotechnology company specializing in regenerative medicine through the development and commercialization of autologous (patient's own) blood-derived stem cell therapies. The company's lead investigational product is ACP-01 (Angiogenic Precursor Cell treatment), a platform targeting ischemic conditions such as Critical Limb Ischemia (CLI), ischemic cardiomyopathy, and angina. ACP-01 is designed to address unmet medical needs, particularly in patients ineligible for standard revascularization procedures. Phase II clinical data re-examination for "no option" CLI indicated that ACP-01 administration was safe and associated with reduced ulcer size and decreased rates of amputation and death.

Recent filings

Filing Released Lang Actions
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 1% confidence The document is the full text of a Form 45-106F1 “Report of Exempt Distribution,” a mandatory Canadian securities regulatory filing providing detailed distribution data under NI 45-106. It is not an earnings release, annual report, or M&A notice, nor a short announcement of a report (“menu vs meal” rule doesn’t apply because this is the actual form). It fits the catch-all category for miscellaneous regulatory filings.
2025-09-15 English
Material change report - English.pdf
Capital/Financing Update Classification · 1% confidence The document is filed as a Canadian NI 51-102F3 Material Change Report and details a non-brokered private placement of common shares for gross proceeds of $280,594. This is a direct update on the company’s fundraising and capital structure. According to the classification definitions, this is a Capital/Financing Update (CAP).
2025-09-09 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a corporate press release announcing a non-brokered private placement (fundraising) of new shares by the company, including details of the amount raised, share price, number of shares, use of proceeds, and regulatory approvals. This falls under updates on company fundraising/financing activities rather than a full annual or interim report, earnings release, or other categories. Therefore it is classified as a Capital/Financing Update.
2025-09-09 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release detailing an increase in a previously closed non-brokered private placement—from C$2.9696 million to C$3 million—including unit pricing, warrant terms, finder’s fees, use of proceeds, and related party transaction disclosures. This is a corporate fundraising/financing update rather than an annual report, earnings release, or regulatory fallback. Therefore, it fits the “Capital/Financing Update” category.
2025-08-01 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 1% confidence The document is labelled “Form 45-106F1 Report of Exempt Distribution” and follows the mandatory SEDAR+ reporting format for Canadian securities regulators. It is not an earnings release, annual or interim report, call transcript, proxy statement, or investor presentation. Nor is it simply announcing a report publication; it is the substantive regulatory submission itself detailing distribution terms, jurisdictions, exemptions relied upon, and compensation information. There is no more specific category for a formal securities exemption distribution report, so the appropriate classification is the fallback “Regulatory Filings” category (RNS).
2025-07-31 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a corporate press release announcing the closing of a sale of therapy convertible debentures, detailing the terms of the financing, use of proceeds, interest, conversion price, and related finder’s fees. This is a clear update on the company’s fundraising and capital structure change via a convertible debt issuance. Therefore, it falls under Capital/Financing Update (CAP).
2025-07-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.